βIII-Tubulin: Biomarker of taxane resistance or drug target?

Expert Opinion on Therapeutic Targets

Volumn 17, Issue 4, 2013, Pages 461-472

  Karki, Roshan ^a   Mariani, Marisa ^a,b   Andreoli, Mirko ^a,b   He, Shiquan ^a   Scambia, Giovanni ^b,c   Shahabi, Shohreh ^a   Ferlini, Cristiano ^a,c  

^a DANBURY HOSPITAL   (United States)

^b CATHOLIC UNIVERSITY   (Italy)

^c Jean Paul IInd Research Foundation   (Italy)

Author keywords

III tubulin; Biomarker; Cancer; Chemotherapy; Docetaxel; Drug resistance; Microtubules; Paclitaxel; Taxanes; Therapeutics; Translational studies; TUBB3; Vinorelbine

Indexed keywords

BETA III TUBULIN; BETA TUBULIN; CISPLATIN; DOCETAXEL; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; MESSENGER RNA; NAVELBINE; PACLITAXEL; TAXANE DERIVATIVE; TUMOR MARKER; UNCLASSIFIED DRUG;

ADVANCED CANCER; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER OF UNKNOWN PRIMARY SITE; CANCER PROGNOSIS; CANCER RESISTANCE; CANCER SURVIVAL; CHEMOSENSITIVITY; COLORECTAL CANCER; DISEASE ASSOCIATION; DNA REPAIR; DRUG MECHANISM; DRUG TARGETING; HEAD AND NECK CANCER; HUMAN; LUNG NON SMALL CELL CANCER; MICROTUBULE; OVARY CANCER; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STOMACH CANCER; TREATMENT RESPONSE;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOLOGICAL MARKERS; BRIDGED COMPOUNDS; DRUG RESISTANCE, NEOPLASM; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASM PROTEINS; NEOPLASMS; TAXOIDS; TUBULIN; TUBULIN MODULATORS;

EID: 84875198728     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.2013.766170     Document Type: Review

References (84)

1. Katsetos CD, Draber P. Tubulins as therapeutic targets in cancer: From bench to bedside. Curr Pharm Des 2012;18(19):2778-92
2. Mariani M, Shahabi S, Sieber S, et al. Class III beta-tubulin (TUBB3): More than a biomarker in solid tumors? Curr Mol Med 2011;11(9):726-31
3. Seve P, Dumontet C. Is class III beta-tubulin a predictive factor in patients receiving tubulin-binding agents? Lancet Oncol 2008;9(2):168-75
4. Verdier-Pinard P, Pasquier E, Xiao H, et al. Tubulin proteomics: Towards breaking the code. Anal Biochem 2009;384(2):197-206
5. Caccamo DV, Herman MM, Frankfurter A, et al. An immunohistochemical study of neuropeptides and neuronal cytoskeletal proteins in the neuroepithelial component of a spontaneous murine ovarian teratoma. Primitive neuroepithelium displays immunoreactivity for neuropeptides and neuron-associated beta-tubulin isotype. Am J Pathol 1989;135(5):801-13
6. Abel MH, Baban D, Lee S, et al. Effects of FSH on testicular mRNA transcript levels in the hypogonadal mouse. J Mol Endocrinol 2009;42(4):291-303
7. Katsetos CD, Herman MM, Mork SJ. Class III beta-tubulin in human development and cancer. Cell Motil Cytoskeleton 2003;55(2):77-96
8. Jordan MA, Kamath K. How do microtubule-targeted drugs work? An overview. Curr Cancer Drug Targets 2007;7(8):730-42
9. Derry WB, Wilson L, Khan IA, et al. Taxol differentially modulates the dynamics of microtubules assembled from unfractionated and purified beta-tubulin isotypes. Biochemistry 1997;36(12):3554-62
10. Mozzetti S, Ferlini C, Concolino P, et al. Class III beta-tubulin overexpression is a prominent mechanism of paclitaxel resistance in ovarian cancer patients. Clin Cancer Res 2005;11(1):298-305
11. Kavallaris M, Kuo DY, Burkhart CA, et al. Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes. J Clin Invest 1997;100(5):1282-93
12. Gan PP, Pasquier E, Kavallaris M. Class III beta-tubulin mediates sensitivity to chemotherapeutic drugs in non small cell lung cancer. Cancer Res 2007;67(19):9356-63
13. McCarroll JA, Gan PP, Liu M, Kavallaris M. betaIII-tubulin is a multifunctional protein involved in drug sensitivity and tumorigenesis in non-small cell lung cancer. Cancer Res 2010;70(12):4995-5003
14. Raspaglio G, Filippetti F, Prislei S, et al. Hypoxia induces class III beta-tubulin gene expression by HIF-1alpha binding to its 3¢ flanking region. Gene 2008;409(1-2):100-8
15. Raspaglio G, De Maria I, Filippetti F, et al. HuR regulates beta-tubulin isotype expression in ovarian cancer. Cancer Res 2010;70(14):5891-900
16. Mozzetti S, Iantomasi R, De Maria I, et al. Molecular mechanisms of patupilone resistance. Cancer Res 2008;68(24):10197-204
17. Carrara L, Guzzo F, Roque DM, et al. Differential in vitro sensitivity to patupilone versus paclitaxel in uterine and ovarian carcinosarcoma cell lines is linked to tubulin-beta-III expression. Gynecol Oncol 2012;125(1):231-6
18. Gan PP, McCarroll JA, Byrne FL, et al. Specific beta-tubulin isotypes can functionally enhance or diminish epothilone B sensitivity in non-small cell lung cancer cells. PLoS ONE 2011;6(6):e21717
19. Koh Y, Jang B, Han SW, et al. Expression of class III beta-tubulin correlates with unfavorable survival outcome in patients with resected non-small cell lung cancer. J Thorac Oncol 2010;5(3):320-5
20. Seve P, Mackey J, Isaac S, et al. Class III beta-tubulin expression in tumor cells predicts response and outcome in patients with non-small cell lung cancer receiving paclitaxel. Mol Cancer Ther 2005;4(12):2001-7
21. Dumontet C, Isaac S, Souquet PJ, et al. Expression of class III beta tubulin in non-small cell lung cancer is correlated with resistance to taxane chemotherapy. Bull Cancer 2005;92(2):E25-30
22. Seve P, Isaac S, Tredan O, et al. Expression of class III {beta}-tubulin is predictive of patient outcome in patients with non-small cell lung cancer receiving vinorelbine-based chemotherapy. Clin Cancer Res 2005;11(15):5481-6
23. Lu HY, Su D, Pan XD, et al. Mutation and expression of multiple treatment response-related genes in a population with locally advanced non-small cell lung cancer. Oncol Lett 2012;3(2):415-20
24. Levallet G, Bergot E, Antoine M, et al. High TUBB3 expression, an independent prognostic marker in patients with early non-small cell lung cancer treated by preoperative chemotherapy, is regulated by K-Ras signaling pathway. Mol Cancer Ther 2012;11(5):1203-13
25. Hayashi Y, Kuriyama H, Umezu H, et al. Class III beta-tubulin expression in tumor cells is correlated with resistance to docetaxel in patients with completely resected non-small-cell lung cancer. Intern Med 2009;48(4):203-8
26. Kaira K, Takahashi T, Murakami H, et al. The role of beta-III-tubulin in non-small cell lung cancer patients treated by taxane-based chemotherapy. Int J Clin Oncol 2012
27. Zhang HL, Ruan L, Zheng LM, et al. Association between class III beta-tubulin expression and response to paclitaxel/vinorelbine-based chemotherapy for non-small cell lung cancer: A meta-analysis. Lung Cancer 2012;77(1):9-15
28. Seve P, Lai R, Ding K, et al. Class III beta-tubulin expression and benefit from adjuvant cisplatin/vinorelbine chemotherapy in operable non-small cell lung cancer: Analysis of NCIC JBR.10. Clin Cancer Res 2007;13(3):994-9
29. Hirai Y, Yoshimasu T, Oura S, et al. Is class III beta-tubulin a true predictive marker of sensitivity to vinorelbine in non-small cell lung cancer? Chemosensitivity data evidence. Anticancer Res 2011;31(3):999-1005
30. Reiman T, Lai R, Veillard AS, et al. Cross-validation study of class III beta-tubulin as a predictive marker for benefit from adjuvant chemotherapy in resected non-small-cell lung cancer: Analysis of four randomized trials. Ann Oncol 2012;23(1):86-93
31. Okuda K, Sasaki H, Dumontet C, et al. Expression of excision repair cross-complementation group 1 and class III beta-tubulin predict survival after chemotherapy for completely resected non-small cell lung cancer. Lung Cancer 2008;62(1):105-12
32. Kang CH, Jang BG, Kim DW, et al. The prognostic significance of ERCC1, BRCA1, XRCC1, and beta-III-tubulin expression in patients with non-small cell lung cancer treated by platinum- and taxane-based neoadjuvant chemotherapy and surgical resection. Lung Cancer 2010;68(3):478-83
33. Azuma K, Sasada T, Kawahara A, et al. Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel. Lung Cancer 2009;64(3):326-33
34. Azuma K, Sasada T, Kawahara A, et al. Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with a combination of cisplatin/docetaxel and concurrent thoracic irradiation. Cancer Chemother Pharmacol 2009;64(3):565-73
35. Ikeda S, Takabe K, Suzuki K. Expression of ERCC1 and class III beta tubulin for predicting effect of carboplatin/paclitaxel in patients with advanced inoperable non-small cell lung cancer. Pathol Int 2009;59(12):863-7
36. Vilmar A, Garcia-Foncillas J, Huarriz M, et al. RT-PCR versus immunohistochemistry for correlation and quantification of ERCC1, BRCA1, TUBB3 and RRM1 in NSCLC. Lung Cancer 2012;75(3):306-12
37. Ferrandina G, Zannoni GF, Martinelli E, et al. Class III beta-tubulin overexpression is a marker of poor clinical outcome in advanced ovarian cancer patients. Clin Cancer Res 2006;12(9):2774-9
38. Ohishi Y, Oda Y, Basaki Y, et al. Expression of beta-tubulin isotypes in human primary ovarian carcinoma. Gynecol Oncol 2007;105(3):586-92
39. Umezu T, Shibata K, Kajiyama H, et al. Taxol resistance among the different histological subtypes of ovarian cancer may be associated with the expression of class III beta-tubulin. Int J Gynecol Pathol 2008;27(2):207-12
40. Su D, Smith SM, Preti M, et al. Stathmin and tubulin expression and survival of ovarian cancer patients receiving platinum treatment with and without paclitaxel. Cancer 2009;115(11):2453-63
41. Hetland TE, Hellesylt E, Florenes VA, et al. Class III beta-tubulin expression in advanced-stage serous ovarian carcinoma effusions is associated with poor survival and primary chemoresistance. Hum Pathol 2011;42(7):1019-26
42. Aoki D, Oda Y, Hattori S, et al. Overexpression of class III beta-tubulin predicts good response to taxane-based chemotherapy in ovarian clear cell adenocarcinoma. Clin Cancer Res 2009;15(4):1473-80
43. De Donato M, Mariani M, Petrella L, et al. Class III beta-tubulin and the cytoskeletal gateway for drug resistance in ovarian cancer. J Cell Physiol 2012;227(3):1034-41
44. Leskela S, Leandro-Garcia LJ, Mendiola M, et al. The miR-200 family controls beta-tubulin III expression and is associated with paclitaxel-based treatment response and progression-free survival in ovarian cancer patients. Endocr Relat Cancer 2011;18(1):85-95
45. Izutsu N, Maesawa C, Shibazaki M, et al. Epigenetic modification is involved in aberrant expression of class III beta-tubulin, TUBB3, in ovarian cancer cells. Int J Oncol 2008;32(6):1227-35
46. Nowak AK, Wilcken NR, Stockler MR, et al. Systematic review of taxane-containing versus non-taxane-containing regimens for adjuvant and neoadjuvant treatment of early breast cancer. Lancet Oncol 2004;5(6):372-80
47. Paradiso A, Mangia A, Chiriatti A, et al. Biomarkers predictive for clinical efficacy of taxol-based chemotherapy in advanced breast cancer. Ann Oncol 2005;16(Suppl 4):iv14-19
48. Pentheroudakis G, Batistatou A, Kalogeras KT, et al. Prognostic utility of beta-tubulin isotype III and correlations with other molecular and clinicopathological variables in patients with early breast cancer: A translational Hellenic Cooperative Oncology Group (HeCOG) study. Breast Cancer Res Treat 2011;127(1):179-93
49. Galmarini CM, Treilleux I, Cardoso F, et al. Class III beta-tubulin isotype predicts response in advanced breast cancer patients randomly treated either with single-agent doxorubicin or docetaxel. Clin Cancer Res 2008;14(14):4511-16
50. Jung M, Koo JS, Moon YW, et al. Overexpression of class III beta tubulin and amplified HER2 gene predict good response to paclitaxel and trastuzumab therapy. PLoS One 2012;7(9):e45127
51. Yuan SF, Zhu LJ, Zheng WE, et al. Expression of beta-tubulin III and survivin in advance stage breast cancer correlates with chemotherapeutic effects of docetaxel. Asian Pac J Cancer Prev 2012;13(1):361-5
52. Chen X, Wu J, Lu H, et al. Measuring beta-tubulin III, Bcl-2, and ERCC1 improves pathological complete remission predictive accuracy in breast cancer. Cancer Sci 2012;103(2):262-8
53. Saussede-Aim J, Matera EL, Ferlini C, Dumontet C. Beta 3-tubulin is induced by estradiol in human breast carcinoma cells through an estrogen-receptor dependent pathway. Cell Motil Cytoskeleton 2009;66(7):378-88
54. Ohtsu A. Current status and future prospects of chemotherapy for metastatic gastric cancer: A review. Gastric Cancer 2005;8(2):95-102
55. Urano N, Fujiwara Y, Doki Y, et al. Clinical significance of class III beta-tubulin expression and its predictive value for resistance to docetaxel-based chemotherapy in gastric cancer. Int J Oncol 2006;28(2):375-81
56. Yu J, Gao J, Lu Z, et al. Serum levels of bIII-Tubulin correlate with clinical outcome in Chinese patients with advanced gastric cancer receiving first-line paclitaxel plus capecitabine. Med Oncol 2012;29(5):3029-34
57. Gao J, Lu M, Yu JW, et al. Thymidine phosphorylase/beta-tubulin III expressions predict the response in Chinese advanced gastric cancer patients receiving first-line capecitabine plus paclitaxel. BMC Cancer 2011;11:177
58. Zheng WE, Chen H, Yuan SF, et al. Overexpression of beta III-tubulin and survivin associated with drug resistance to docetaxel-based chemotherapy in advanced gastric cancer. J BUON 2012;17(2):284-90
59. Jirasek T, Cipro S, Musilova A, et al. Expression of class III beta-tubulin in colorectal carcinomas: An immunohistochemical study using TU-20 & TuJ-1 antibody. Indian J Med Res 2009;129(1):89-94
60. Mariani M, Zannoni GF, Sioletic S, et al. Gender influences the Class III and V beta-tubulin ability to predict poor outcome in colorectal cancer. Clin Cancer Res 2012;18(10):2964-75
61. Zmuda JM, Cauley JA, Kuller LH, Ferrell RE. A common promoter variant in the cytochrome P450c17alpha (CYP17) gene is associated with bioavailability testosterone levels and bone size in men. J Bone Miner Res 2001;16(5):911-17
62. Yousefi M, Karmaus W, Mudd LM, et al. Expression of CYP19 and CYP17 is associated with leg length, weight, and BMI. Obesity (Silver Spring) 2011;19(2):436-41
63. Terry S, Ploussard G, Allory Y, et al. Increased expression of class III beta-tubulin in castration-resistant human prostate cancer. Br J Cancer 2009;101(6):951-6
64. Forde JC, Perry AS, Brennan K, et al. Docetaxel maintains its cytotoxic activity under hypoxic conditions in prostate cancer cells. Urol Oncol 2012;30(6):912-19
65. Elsberger B, Lankston L, Orange C, et al. Expression of hypoxia inducible factor-1 alpha in matched hormone naive and castrate-resistant prostate cancer specimens. Cancer Biomark 2010;8(1):1-9
66. Egevad L, Valdman A, Wiklund NP, et al. Beta-tubulin III expression in prostate cancer. Scand J Urol Nephrol 2010;44(6):371-7
67. Ploussard G, Terry S, Maille P, et al. Class III beta-tubulin expression predicts prostate tumor aggressiveness and patient response to docetaxel-based chemotherapy. Cancer Res 2010;70(22):9253-64
68. Ferrandina G, Martinelli E, Zannoni GF, et al. Expression of class III beta tubulin in cervical cancer patients administered preoperative radiochemotherapy: Correlation with response to treatment and clinical outcome. Gynecol Oncol 2007;104(2):326-30
69. Koh Y, Kim TM, Jeon YK, et al. Class III beta-tubulin, but not ERCC1, is a strong predictive and prognostic marker in locally advanced head and neck squamous cell carcinoma. Ann Oncol 2009;20(8):1414-19
70. Seve P, Reiman T, Lai R, et al. Class III beta-tubulin is a marker of paclitaxel resistance in carcinomas of unknown primary site. Cancer Chemother Pharmacol 2007;60(1):27-34
71. Seve P, Reiman T, Isaac S, et al. Protein abundance of class III beta-tubulin but not Delta2-alpha-tubulin or tau is related to paclitaxel response in carcinomas of unknown primary site. Anticancer Res 2008;28(2B):1161-7
72. Kaira K, Serizawa M, Koh Y, et al. Expression of excision repair cross-complementation group 1, breast cancer susceptibility 1, and beta III-tubulin in thymic epithelial tumors. J Thorac Oncol 2011;6(3):606-13
73. Zhu C, Luo J, Shi H, et al. Expression of tubulin, p53, ki67, receptors for estrogen, and progesterone in endometrial cancer. Eur J Gynaecol Oncol 2009;30(5):514-17
74. Vandenput I, Capoen A, Coenegrachts L, et al. Expression of ERCC1, p53, and class III beta-tubulin do not reveal chemoresistance in endometrial cancer: Results from an immunohistochemical study. Int J Gynecol Cancer 2011;21(6):1071-7
75. Roque DM, Santin AD. Updates in therapy for uterine serous carcinoma. Curr Opin Obstet Gynecol 2013;25(1):29-37
76. Akasaka K, Maesawa C, Shibazaki M, et al. Loss of class III beta-tubulin induced by histone deacetylation is associated with chemosensitivity to paclitaxel in malignant melanoma cells. J Invest Dermatol 2009;129(6):1516-26
77. Miyamoto A, Akasaka K, Oikawa H, et al. Immunohistochemical study of HER2 and TUBB3 proteins in extramammary Paget disease. Am J Dermatopathol 2010;32(6):578-85
78. Ishida M, Kushima R, Okabe H. Aberrant expression of class III beta-tubulin in basal cell carcinoma of the skin. Oncol Rep 2009;22(4):733-7
79. Yoon SO, Kim WY, Go H, et al. Class III beta-tubulin shows unique expression patterns in a variety of neoplastic and non-neoplastic lymphoproliferative disorders. Am J Surg Pathol 2010;34(5):645-55
80. Leandro-Garcia LJ, Leskela S, Landa I, et al. Tumoral and tissue-specific expression of the major human beta-tubulin isotypes. Cytoskeleton (Hoboken) 2010;67(4):214-23
81. Ferrandina G, Mariani M, Andreoli M, et al. Novel drugs targeting microtubules: The role of epothilones. Curr Pharm Des 2012;18(19):2793-803
82. Dumontet C, Jordan MA, Lee FF. Ixabepilone: Targeting beta III-tubulin expression in taxane-resistant malignancies. Mol Cancer Ther 2009;8(1):17-25
83. Riobo NA, Lu K, Emerson Jr. C.P. Hedgehog signal transduction: Signal integration and cross talk in development and cancer. Cell Cycle 2006;5(15):1612-15
84. Mozzetti S, Martinelli E, Raspaglio G, et al Gli family transcription factors are drivers of patupilone resistance in ovarian cancer. Biochem Pharmacol 2012;84(11):1409-18